Mucin O-glycosylation is characterized in
cancer by aberrant expression of immature
carbohydrate structures (Tn, T, and sialyl-Tn
antigens). The
UDP-
N-acetyl-D-galactosamine:
polypeptide N-acetylgalactosaminyltransferases (
ppGalNAc-T) family
enzymes regulate the initial steps of
mucin O-glycosylation and could be responsible for the altered glycosylation observed in
cancer. Considering that we recently found the ppGalNAc-T6
mRNA expressed in
breast carcinomas, we produced a highly specific
monoclonal antibody (MAb T6.3) to assess the expression profile of ppGalNAc-T6
protein product in breast tissues. The expression of ppGalNAc-T6 by
breast carcinoma cells was confirmed on MCF-7 and T47D cell lines. In
formalin-fixed tissues, ppGalNAc-T6 expression was observed in 60/74 (81%) breast
cancers, 21/23 (91.3%) adjacent
ductal carcinoma in situ (
DCIS), 4/20 benign breast lesions (2/2 sclerosing adenosis and 2/13
fibroadenoma), and in 0/5 normal breast samples. We observed a statistically significant association of ppGalNAc-T6 expression with T1
tumor stage. This fact, as well as the observation that ppGalNAc-T6 was strongly expressed in sclerosing adenosis and in most
DCIS, suggests that ppGalNAc-T6 expression could be an early event during human breast
carcinogenesis. Considering that an abnormal O-glycosylation greatly contributes to the phenotype and biology of
breast cancer cells, ppGalNAc-T6 expression could provide new insights about
breast cancer glycobiology.